These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
571 related articles for article (PubMed ID: 33839362)
1. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362 [TBL] [Abstract][Full Text] [Related]
2. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis. Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736 [TBL] [Abstract][Full Text] [Related]
3. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer. Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288 [TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer. Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367 [TBL] [Abstract][Full Text] [Related]
5. First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis. Mutlu H; Bozcuk H; Artaç M; Eser İ J Cancer Res Ther; 2023 Apr; 19(Supplement):S6-S11. PubMed ID: 37147977 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study. Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798 [TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis. Zhang S; Li S; Cheng Y Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504 [TBL] [Abstract][Full Text] [Related]
9. [Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer]. Zhang SY; Wang Y Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):98-103. PubMed ID: 33472320 [TBL] [Abstract][Full Text] [Related]
10. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer. Konala VM; Madhira BR; Ashraf S; Graziano S Oncology; 2020; 98(11):749-754. PubMed ID: 32663833 [TBL] [Abstract][Full Text] [Related]
11. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report. Xue L; Chen B; Lin J; Peng J Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805 [TBL] [Abstract][Full Text] [Related]
12. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. Tian Y; Zhai X; Han A; Zhu H; Yu J J Hematol Oncol; 2019 Jun; 12(1):67. PubMed ID: 31253167 [TBL] [Abstract][Full Text] [Related]
13. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors. Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of PD-1/PD-L1 Inhibitor and Chemotherapy in Treatment of Advanced Small Cell Lung Cancer. Tian W; Zhao J; Wang W; Li Y Altern Ther Health Med; 2024 Jul; 30(7):252-257. PubMed ID: 37971453 [TBL] [Abstract][Full Text] [Related]
15. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy. Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678 [TBL] [Abstract][Full Text] [Related]
17. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival. Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332 [TBL] [Abstract][Full Text] [Related]
18. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Paz-Ares L; Garassino MC; Chen Y; Reinmuth N; Hotta K; Poltoratskiy A; Trukhin D; Hochmair MJ; Özgüroğlu M; Ji JH; Statsenko G; Conev N; Bondarenko I; Havel L; Losonczy G; Xie M; Lai Z; Godin-Heymann N; Mann H; Jiang H; Shrestha Y; Goldman JW Clin Cancer Res; 2024 Feb; 30(4):824-835. PubMed ID: 37801329 [TBL] [Abstract][Full Text] [Related]
19. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer. Gadgeel SM Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression]. Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]